Literature DB >> 27149125

Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-α) Levels in Patients with Psoriasis and their Correlation with Disease Severity.

Betul Sereflican1, Nadir Goksugur, Guler Bugdayci, Mualla Polat, Ali Haydar Parlak.   

Abstract

Psoriasis is a chronic, autoimmune, and inflammatory disease of unknown etiology, characterized by T lymphocyte mediated keratinocyte proliferation. In recent years the relationship between psoriasis and adipose tissue cytokines has been reported. Psoriasis as a triggering factor for the immune and metabolic disorders can be associated with diabetes mellitus, abnormal lipid metabolism, and metabolic syndrome. In this study we assessed the adipose tissue cytokines visfatin, adiponectin, and tumor necrosis factor-α (TNF-α) levels in psoriasis patients and evaluated the relationship between disease severity and cytokines. The study included 42 patients with psoriasis and 42 healthy individuals. Visfatin, adiponectin, and TNF-α levels were measured in both the psoriasis and the control group. The disease severity index was assessed in psoriatic patients by means of PASI. The relationship between visfatin, adiponectin, TNF-α, PASI score, and obesity was evaluated. When serum TNF-α, adiponectin, and visfatin levels of the patient group were compared with those of the control group, the TNF-α levels were statistically higher (p = 0.00) and the adiponectin levels were statistically lower (p = 0.024). The visfatin levels were higher in the psoriatic patients compared to the control group, but this difference was not statistically significant (p = 0.73). The relationship between PASI-TNF-α and between PASI-adiponectin was statistically significant (p = 0.009 and p = 0.004). A positive correlation was observed between body mass index (BMI) and visfatin (p = 0.031). These results indicate that TNF-α and adiponectin play a part in psoriasis etiopathogenesis and can be used as parameters to evaluate the severity of the disease. However, the role of visfatin in psoriasis pathogenesis is unclear. Further clinical studies are needed to clarify the effect of visfatin in psoriatic patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27149125

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  16 in total

1.  Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors.

Authors:  Camila Cataldi; Naiara Lourenço Mari; Marcell Alysson Batisti Lozovoy; Ligia Márcia Mário Martins; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi; Andréa Name Colado Simão
Journal:  Inflamm Res       Date:  2019-05-06       Impact factor: 4.575

2.  Analysis of molecular and clinical parameters of 4-year adalimumab therapy in psoriatic patients.

Authors:  Dominika Wcisło-Dziadecka; Beniamin Grabarek; Celina Kruszniewska-Rajs; Andrzej Swinarew; Krzysztof Jasik; Beata Rozwadowska; Agata Krawczyk
Journal:  Postepy Dermatol Alergol       Date:  2020-11-07       Impact factor: 1.837

3.  Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis.

Authors:  Qian Zou; Jiawei Si; Yatao Guo; Jiayu Yu; Huijuan Shi
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 4.  The Role of Adiponectin in the Skin.

Authors:  Jieun Oh; Yeongyeong Lee; Sae-Woong Oh; TianTian Li; Jiwon Shin; See-Hyoung Park; Jongsung Lee
Journal:  Biomol Ther (Seoul)       Date:  2022-05-01       Impact factor: 4.634

Review 5.  TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization.

Authors:  Olivier Gouin; Killian L'Herondelle; Nicolas Lebonvallet; Christelle Le Gall-Ianotto; Mehdi Sakka; Virginie Buhé; Emmanuelle Plée-Gautier; Jean-Luc Carré; Luc Lefeuvre; Laurent Misery; Raphaele Le Garrec
Journal:  Protein Cell       Date:  2017-03-31       Impact factor: 14.870

6.  Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients.

Authors:  Haneya A A Anani; Amany M Tawfeik; Soheir S Maklad; Abeer M Kamel; Enas E El-Said; Asmaa S Farag
Journal:  Psoriasis (Auckl)       Date:  2020-05-21

7.  Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis.

Authors:  Fan Bai; Wen Zheng; Yan Dong; Juan Wang; Malgorzata A Garstka; Ruilian Li; Jingang An; Huiqun Ma
Journal:  Oncotarget       Date:  2017-11-01

Review 8.  New insights into different adipokines in linking the pathophysiology of obesity and psoriasis.

Authors:  Yi Kong; Suhan Zhang; Ruifang Wu; Xin Su; Daoquan Peng; Ming Zhao; Yuwen Su
Journal:  Lipids Health Dis       Date:  2019-09-14       Impact factor: 4.315

9.  Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis.

Authors:  Dominika Wcisło-Dziadecka; Beniamin Grabarek; Andrzej S Swinarew; Beata Rozwadowska; Nikola Zmarzły; Joanna Gola
Journal:  Postepy Dermatol Alergol       Date:  2020-05-06       Impact factor: 1.837

Review 10.  Current Developments in the Immunology of Psoriasis.

Authors:  Franziska Grän; Andreas Kerstan; Edgar Serfling; Matthias Goebeler; Khalid Muhammad
Journal:  Yale J Biol Med       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.